When does the fidaxomicin (Dificid) patent expire?
The exact patent expiration date depends on which specific patent(s) cover fidaxomicin in a given country, because drug protection typically includes multiple patents and different legal timelines (for example, formulation, polymorph, manufacturing, and additional exclusivity provisions). The provided information does not include the relevant patent numbers or jurisdictions, so a precise expiration date can’t be determined from it.
Which patents matter for fidaxomicin, and how do you find the right expiration date?
To pin down the expiration date, you generally need:
- The drug product name (fidaxomicin; brand name often referenced as Dificid) and the approved country/market.
- The specific patent family or publication(s) listed for that product in that market.
- Any adjusted term, pediatric exclusivity, or patent term extensions that may shift the final expiry date.
Without the patent documents or the country/market, there is no single “the” expiration date.
What should you specify so I can give the exact date?
Reply with:
1) The country/market (e.g., US, EP/UK, Germany, Japan), and
2) Whether you mean the first generic entry date (often tied to exclusivity/market protection) or the last patent expiry date (often tied to patent term).
With that, I can map the relevant patents to their expiry timelines.
Why there may be different “expiration dates” people see online
Different sources often report different milestones:
- last patent expiry versus exclusivity expiration,
- patent expiry versus regulatory exclusivity that still blocks generic substitution,
- country-by-country differences.
So two dates might both be correct depending on what protection they refer to.
Sources
No sources were provided with your question, so I can’t cite any authoritative patent-expiry date here.